首页|黄芩苷在肺动脉高压中的研究进展

黄芩苷在肺动脉高压中的研究进展

扫码查看
肺动脉高压是一种以肺动脉血管阻力持续升高、肺血管阻塞、血管重构、右心室肥厚、功能衰竭为特征的疾病,发病机制包括肺动脉内皮细胞功能障碍和肺动脉平滑肌细胞增殖,目前迫切需要新的治疗药物和方法.研究表明,黄芩苷对肺动脉高压的治疗有效,但具体作用机制不明.本文综述了黄芩苷药代动力学及对肺动脉高压的潜在治疗机制,主要包括抗炎反应、稳定细胞外基质、减轻氧化应激、抑制肺平滑肌细胞增殖、内皮-间质转化等,为中药治疗肺动脉高压提供依据.
The Research Progress of Baicalin in Pulmonary Hypertension
Pulmonary hypertension is a disease characterized by sustained increase of pulmonary vascular resistance, also pulmonary vascular obstruction, vascular remodeling, right ventricular hypertrophy,and function failures.The pathogenesis of pulmonary arterial hypertension includes pulmonary endothelial cell dysfunction and pulmonary smooth muscle cell proliferation.New drugs and treatment options are urgently needed in clinical practices.Studies have shown that baicalin is effective in the treatment of pulmonary hypertension,but mechanisms remain unclear.This article reviewed the pharmacokinetics of baicalin and the potential therapeutic mechanisms of baicalin for pulmonary hypertension,including anti-inflammatory response,stabilization of extracellular matrix, reduction of oxidative stress, inhibition of lung smooth muscle cell proliferation, endothelium-interstitial transformation,providing a knowledge basis for traditional Chinese medicine treatment of pulmonary arterial hypertension.

BaicalinPulmonary hypertensionPulmonary smooth muscle cellsInflammationEndothelium-interstitial transformationOxidative stress

吕俊刚、翟莉、曹甜甜、单青、胡凤英、李佳月

展开 >

武警北京市总队医院内三科,北京 100027

唐山中心医院心血管内科,河北 唐山 063000

天津医科大学研究生院,天津 300192

解放军总医院第一医学中心心血管内科,北京 100853

展开 >

黄芩苷 肺动脉高压 肺动脉平滑肌细胞 炎症 内皮-间质转化 氧化应激

河北省医学科学研究项目

20221849

2024

标记免疫分析与临床
中国同辐股份有限公司

标记免疫分析与临床

CSTPCD
影响因子:0.978
ISSN:1006-1703
年,卷(期):2024.31(3)
  • 34